Drug Trial Radar · NCT00925301
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Oct 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Oct 23, 2009
Primary completion
Jun 12, 2012
Study completion Jan 29, 2014
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to compare the effect of migalastat (123 milligrams \[mg\] of migalastat \[equivalent to 150 mg of migalastat hydrochloride\]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).
Conditions
- Fabry Disease
Interventions
migalastat hydrochlorideDrug
Oral capsule QOD
PlaceboDrug
Oral capsule QOD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) InclusionsTime frame: Baseline, Month 6
Locations
28 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
San Francisco, California
Site not named
Decatur, Georgia
Site not named
Chicago, Illinois
Site not named
Kansas City, Kansas
Site not named
Boston, Massachusetts
Site not named
Grand Rapids, Michigan
Site not named
New York, New York
Site not named
Pittsburgh, Pennsylvania
Site not named
Dallas, Texas
Site not named
Salt Lake City, Utah
Site not named
Springfield, Virginia
Site not named
Seattle, Washington
Site not named
Buenos Aires, Argentina
Site not named
Adelaide, Australia
Site not named
Parkville, Australia
Site not named
Porto Alegre, Brazil
Site not named
São Paulo, Brazil
Site not named
Montreal, Quebec, Canada
Site not named
Copenhagen, Denmark
Site not named
Cairo, Egypt
Site not named
Garches, France
Site not named
Roma, Italy
Site not named
Warsaw, Poland
Site not named
Barcelona, Spain
Site not named
Zaragoza, Spain
Site not named
Ankara, Turkey (Türkiye)
Site not named
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.